Develops mRNA-based CAR-T cell therapies targeting autoimmune diseases, utilizing a proprietary platform to engineer safer and more potent therapeutic candidates. This approach addresses the limitations of traditional cell therapies by improving efficacy and reducing adverse effects, with ongoing clinical trials for conditions like myasthenia gravis.
Funding
$130M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional CAR-T cell therapies, while effective for certain cancers, have shown limited success in treating autoimmune diseases due to safety concerns and challenges in targeting the specific immune cells responsible for autoimmunity. Existing treatments often involve broad immunosuppression, leading to increased risk of infection and other complications.
Solution
Cartesian Therapeutics is developing mRNA-based CAR-T cell therapies designed to selectively target and eliminate autoreactive immune cells in patients with autoimmune disorders. Their approach utilizes a proprietary mRNA platform to engineer CAR-T cells with enhanced safety profiles and improved specificity for disease-driving cells. By transiently expressing the CAR construct via mRNA, the therapy aims to minimize off-target effects and cytokine release syndrome, common limitations of conventional CAR-T therapies. This targeted approach seeks to provide durable disease remission while preserving overall immune function. Clinical trials are underway to evaluate the efficacy and safety of these therapies in conditions such as myasthenia gravis.
Target Audience
The primary target audience includes patients with autoimmune diseases such as myasthenia gravis who have failed to respond to conventional therapies, as well as physicians specializing in rheumatology, neurology, and immunology.
Features
- mRNA-based CAR-T cell engineering for transient CAR expression and reduced toxicity
- Target antigen selection focused on autoreactive immune cell populations
- Proprietary platform for optimizing CAR-T cell specificity and activity
- cGMP manufacturing facility for producing clinical-grade cell therapies
- Clinical trials evaluating safety and efficacy in multiple autoimmune indications